Last reviewed · How we verify
Valsartan (-based therapy) arm
Valsartan (-based therapy) arm is a Angiotensin II receptor blocker (ARB) Small molecule drug developed by Hippocration General Hospital. It is currently FDA-approved for Hypertension, Heart failure with reduced ejection fraction, Post-myocardial infarction left ventricular dysfunction.
Valsartan blocks angiotensin II type 1 (AT1) receptors, preventing vasoconstriction and aldosterone release to lower blood pressure.
Valsartan is a type-1 angiotensin II receptor antagonist used to treat conditions such as hypertension, heart failure, and heart failure due to coronary artery disease. It is typically administered as a small molecule, either as monotherapy or in combination with other medications like hydrochlorothiazide or amlodipine.
At a glance
| Generic name | Valsartan (-based therapy) arm |
|---|---|
| Sponsor | Hippocration General Hospital |
| Drug class | Angiotensin II receptor blocker (ARB) |
| Target | AT1 receptor (Angiotensin II type 1 receptor) |
| Modality | Small molecule |
| Therapeutic area | Cardiovascular |
| Phase | FDA-approved |
Mechanism of action
Valsartan is an angiotensin II receptor blocker (ARB) that selectively antagonizes AT1 receptors on vascular smooth muscle and adrenal tissue. By blocking angiotensin II signaling, it causes vasodilation, reduces peripheral vascular resistance, and decreases aldosterone-mediated sodium and water retention, resulting in reduced blood pressure and improved cardiac function.
Approved indications
- Hypertension
- Heart failure with reduced ejection fraction
- Post-myocardial infarction left ventricular dysfunction
Common side effects
- Dizziness
- Fatigue
- Hyperkalemia
- Cough
- Hypotension
Key clinical trials
- Antihypertensive Pharmacological Therapy With Mineralocorticoid Receptor Antagonists in Obese Hypertensive Patients (PHASE4)
- Effects of Valsartan vs Amlodipine and Low BP on Kidney Outcomes in Essential Hypertension (PHASE3)
- A Randomized, Double-blind Controlled Study Comparing LCZ696 to Medical Therapy for Comorbidities in HFpEF Patients (PHASE3)
- Safety and Efficacy of ARNI After LVAD ImplanT (SEAL-IT) Study (PHASE4)
- Systematic Withdrawal of Neurohumoral Blocker Therapy in Optimally Responding CRT Patients (PHASE4)
- Valsartan Intensified Primary Care Reduction of Blood Pressure Study (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Valsartan (-based therapy) arm CI brief — competitive landscape report
- Valsartan (-based therapy) arm updates RSS · CI watch RSS
- Hippocration General Hospital portfolio CI
Frequently asked questions about Valsartan (-based therapy) arm
What is Valsartan (-based therapy) arm?
How does Valsartan (-based therapy) arm work?
What is Valsartan (-based therapy) arm used for?
Who makes Valsartan (-based therapy) arm?
What drug class is Valsartan (-based therapy) arm in?
What development phase is Valsartan (-based therapy) arm in?
What are the side effects of Valsartan (-based therapy) arm?
What does Valsartan (-based therapy) arm target?
Related
- Drug class: All Angiotensin II receptor blocker (ARB) drugs
- Target: All drugs targeting AT1 receptor (Angiotensin II type 1 receptor)
- Manufacturer: Hippocration General Hospital — full pipeline
- Therapeutic area: All drugs in Cardiovascular
- Indication: Drugs for Hypertension
- Indication: Drugs for Heart failure with reduced ejection fraction
- Indication: Drugs for Post-myocardial infarction left ventricular dysfunction
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing